GlassScriptPhysician profile
Raja Ogirala
NPI 1427044023
$6,675.31
in general payments reported to CMS, 2019-2025
27 companies · $595 in 2025
The $595 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $681 · 2021: $1,250 · 2022: $763 · 2023: $1,251 · 2024: $1,152 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,990 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,989.70 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,642.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,483.24 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,376.59 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $251.26 | 2021-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $248.31 | 2023-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $201.53 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $147.67 | 2021-2024 | Dupixent |
| Philips North America LLC | $136.33 | 2019-2023 | |
| Electromed, INC. | $116.36 | 2019 | |
| Advanced Respiratory, INC | $113.94 | 2020-2021 | |
| Genzyme Corporation | $111.74 | 2023-2025 | |
| Amgen INC. | $110.50 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $104.27 | 2020-2025 | Glassia |
| Mylan Specialty L.P. | $97.36 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $62.67 | 2023-2025 | Capvaxive, Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $54.18 | 2023-2024 | |
| Genentech USA, INC. | $53.84 | 2019 | |
| Circassia INC. | $48.48 | 2019-2021 | |
| Baxter Healthcare | $45.56 | 2023 | Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $44.70 | 2022-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $41.06 | 2019 | |
| Fisher & Paykel Healthcare INC | $41.00 | 2024 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $39.96 | 2019 | |
| Verona Pharma, INC. | $31.28 | 2025 | Ohtuvayre |
| Shire North American Group INC | $29.87 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $28.67 | 2024 | Lumryz |
| Paratek Pharmaceuticals, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Ogirala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.